The Alethios Early-Stage Program supports teams across consumer health, CPG, biotech, and academia with discounted access to Alethios—enabling rigorous, decentralized human studies without waiting for large budgets or traditional clinical infrastructure.
Alethios provides end-to-end research infrastructure for decentralized clinical studies: a platform for ideation and execution, that can be paired with a network of scientists and experts to guide your work. We believe everyone should have the opportunity to conduct human health research — and that starts with early-stage teams.
The program is built around three goals: cost-effective trials, accelerated timelines, and access to a network of scientists and Alethios partners.
.svg)
%201.svg)
This program is specifically for those early in their journey — when access, not ambition, is the limiting factor. Alethios has already partnered with a number of startups pushing the boundaries of human health research.
.svg)
Working in chronically underfunded or under-researched areas of human health.
Addressing conditions or populations historically excluded from traditional clinical research.
Facing barriers in areas where early human evidence generation has been prohibitively expensive, logistically complex, or otherwise out of reach
The Early-Stage Program provides reduced-cost access to the Alethios research platform and its full suite of support features. This may include reduced licensing and support fees, or a pay-what-you-can model depending on your situation. Each offering is tailored to the applicant — potential benefits may include:
.svg)
If the program feels like a good fit for your team, we’d love to learn more. To get started, please use the application link at the bottom of the page (~15 minutes).
Applications are reviewed on a rolling basis, and you can expect a response within 1–2 weeks confirming whether you’ve been accepted.
If accepted, we will schedule an introductory call. During this conversation, we’ll discuss your intervention, study design, endpoints, timeline, and anticipated costs.
The Early-Stage Program offers the same rigorous research platform used by established companies, but at significantly reduced pricing for eligible teams. Participants also receive closer partnership and support to design and execute meaningful human studies — whether pilots, observational work, or early interventional trials. The program is intentionally selective and cohort-based, focused on helping early innovators and structurally disadvantaged teams generate credible human evidence earlier in their journey.
Yes. The Early-Stage Program typically involves a commitment to run 1–2 studies under a 6-month agreement. That said, we understand that early-stage teams operate with different constraints, and in certain cases we can structure the engagement on a month-to-month basis depending on the situation
We encourage applicants to provide an estimated monthly budget alongside a range of study goals — from a minimum viable study to an ideal or "dream" study. This can include considerations like participant count, study duration, and endpoint type (e.g., surveys, wearables, or biomarker testing). If accepted, we'll work with you to maximize what's possible within your budget.
Yes. Recruitment is built into the Alethios platform. Through the Early-Stage Program, teams can recruit participants directly from the Alethiad Participant Community at a highly discounted rate — and in some cases, at no cost. Many teams also supplement recruitment through their existing customer base, community, or mailing lists, depending on their study goals and target population.
.svg)